医学
胰高血糖素样肽1受体
危险系数
四分位间距
肠促胰岛素
内科学
二肽基肽酶-4
胃肠病学
队列
比率
艾塞那肽
胰高血糖素样肽-1
置信区间
胰高血糖素样肽-2
糖尿病
2型糖尿病
受体
内分泌学
兴奋剂
生物化学
肽
化学
作者
Peter Ueda,Viktor Wintzell,Mads Melbye,Björn Eliasson,Jonas Söderling,Soffia Guðbjörnsdóttir,Kristian Hveem,Christian Jonasson,Henrik Svanström,Anders Hviid,Björn Pasternak
标识
DOI：10.1016/j.cgh.2023.08.034
摘要
Concerns have been raised that the incretin-based diabetes drugs dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists may increase the risk of intestinal obstruction. We aimed to assess the association between use of DPP4 inhibitors and GLP-1 receptor agonists and the risk of intestinal obstruction.
科研通智能强力驱动
Strongly Powered by AbleSci AI
毛豆
丰知然
yar
杳鸢
从容芮
彭于彦祖
嗯哼
123
Billy
坚强的广山
Ganlou
子车茗
爱静静
mhl11
pluto
小鱼爱吃肉
张益萌
良辰
个性的紫菜
HEIKU
皖公网安备34019202002308
